Evidence-Based Medical News

Mode

All Oncology Infectious Disease Neurology Psychiatry Cardiology Diabetes & Endocrinology Pediatrics Allergy & Immunology Rheumatology Primary Care & Family Medicine Gastroenterology Nutrition & Obesity Medicine Orthopedics & Sports Medicine OB/GYN & Women's Health Radiology & Imaging Genetics & Precision Medicine Anesthesiology & Pain Medicine Pulmonology & Critical Care Physical Medicine & Rehab Nephrology Emergency Medicine Urology Ophthalmology Hematology Dermatology Geriatrics & Aging ENT (Otolaryngology) Palliative Care

Research

Clinical Trials Drug Pipeline Weekly Digests

Reference

Conditions Medications

Community

Text Size

Log in / Sign up

carfilzomib

2 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of carfilzomib

54 trials tracked of carfilzomib: 10 in phase 3 or 4 and 7 with published results. The most-cited published study has 429 citations.

54Trials tracked

10Phase 3 & 4

0Recruiting

7With published results

Phase distribution

Phase 4 1 Phase 3 9 Phase 2 37 Phase 1 7

Phase 3 Study of Carfilzomib, Daratumumab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma. Completed · 429 cited
Phase 3 Multinational Clinical Study Comparing Isatuximab, Carfilzomib And Dexamethasone To Carfilzomib And Dexamethasone In Relapse And/Or Refractory Multiple Myeloma Patients Completed · 387 cited
Phase 3 Once-weekly Versus Twice-weekly Carfilzomib in Combination With Dexamethasone in Adults With Relapsed and Refractory Multiple Myeloma Completed · 208 cited
Phase 3 Phase 3 Study of Carfilzomib, Melphalan, Prednisone vs Bortezomib, Melphalan, Prednisone in Newly Diagnosed Multiple Myeloma Completed · 131 cited
Phase 3 A Study Comparing Once-weekly vs Twice-weekly Carfilzomib in Combination With Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma Completed · 13 cited
Phase 3 Carfilzomib in Combination With Dexamethasone (Kd) in Chinese Patients With Relapsed & Refractory Multiple Myeloma Completed · 11 cited

Show 44 more trials

Phase 4 A Study to Evaluate the Efficacy and Safety of Ixazomib in Combination With Lenalidomide and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma Initially Treated With an Injection of Proteasome Inhibitor-Based Therapy Completed · 2 cited
Phase 3 Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone (CRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Relapsed Multiple Myeloma Completed
Phase 3 A Study of Carfilzomib vs Best Supportive Care in Subjects With Relapsed and Refractory Multiple Myeloma Completed
Phase 3 Phase 3 Study With Carfilzomib and Dexamethasone Versus Bortezomib and Dexamethasone for Relapsed Multiple Myeloma Patients Completed
Phase 2 Study of Carfilzomib With Irinotecan in Irinotecan-Sensitive Malignancies and Small Cell Lung Cancer Patients Completed
Phase 2 LCI-HEM-MYE-CRD-004 (MMRC-073 CARJAK): Study of CRD for Carfilzomib-Refractory Multiple Myeloma Completed
Phase 2 Phase 1b/2 Study of Carfilzomib, Carboplatin, and Etoposide in Patients With Previously Untreated Extensive Stage Small-cell Lung Cancer Completed
Phase 2 Phase 2 Study of Carfilzomib in Relapsed and Refractory Multiple Myeloma Completed
Phase 2 Phase 2 Trial of Carfilzomib for Metastatic Castration-resistant Prostate Cancer Following Treatment Completed
Phase 2 A Dose Escalation Study of Carfilzomib Taken With Thalidomide and Dexamethasone in Relapsed AL Amyloidosis Completed
Phase 2 Carfilzomib, Lenalidomide, and Dexamethasone in New Multiple Myeloma Patients Completed
Phase 2 Carfilzomib, Lenalidomide, and Dexamethasone for Smoldering Multiple Myeloma Completed
Phase 2 Infusional Carfilzomib in Patients With Relapsed or Refractory Multiple Myeloma Completed
Phase 2 Study of the Combination of Panobinostat and Carfilzomib in Patients With Relapsed/Refractory Multiple Myeloma Completed
Phase 2 Carfilzomib, Rituximab and Dexamethasone in Waldenstrom's Macroglobulinemia Completed
Phase 2 Study of High Dose Carfilzomib in Multiple Myeloma Patients Who Have Progressed On Standard Dose Carfilzomib Completed
Phase 2 Phase 1/2 Study of Carfilzomib for the Prevention of Relapse and GVHD in Allo-HCT for Hematologic Malignancies Completed
Phase 2 Carfilzomib, Rituximab, and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Lymphoma Completed
Phase 2 A Study of Weekly Carfilzomib in Combination With Dexamethasone for Progressive Multiple Myeloma Completed
Phase 2 S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma Completed
Phase 2 A Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens Completed
Phase 2 Cyclophosphamide, Carfilzomib, Thalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed Active Multiple Myeloma Completed
Phase 2 Carfilzomib for the Treatment of Patients With Advanced Neuroendocrine Cancers Completed
Phase 2 Study of Initial Treatment With Elotuzumab, Carfilzomib, Lenalidomide and Dexamethasone in Multiple Myeloma Completed
Phase 2 High-Dose Weekly Carfilzomib Plus Cyclophosphamide and Dexamethasone in the Treatment of Relapsed Multiple Myeloma Completed
Phase 2 Carfilzomib in Refractory Renal Cell Carcinoma (RCC) Completed
Phase 2 Phase 2 Study of Carfilzomib in Relapsed Multiple Myeloma Completed
Phase 2 Carfilzomib and Melphalan Before Stem Cell Transplant in Treating Patients With Multiple Myeloma Completed
Phase 2 Carfilzomib + High Dose Melphalan as Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation Completed
Phase 2 Carfilzomib, Lenalidomide, and Dexamethasone Before and After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma Completed
Phase 2 Combination Therapy With Carfilzomib, Romidepsin, Lenalidomide in Patients With Relapsed or Refractory B- and T-cell Lymphomas Completed
Phase 2 Study of Early Relapsed, Lenalidomide-refractory Subjects Eligible for Carfilzomib Triplet Completed
Phase 2 Study of the Safety and Pharmacokinetics of Carfilzomib in Patients With Relapsed and Refractory Multiple Myeloma and Varying Degrees of Renal Function Completed
Phase 2 A Phase II Study of Carfilzomib in Relapsed Waldenström's Macroglobulinemia (WM) IST-CAR-531 Completed
Phase 2 Study of BTK Inhibitor, Ibrutinib in Combination With Carfilzomib in Subjects With Relapsed and Refractory Multiple Myeloma Completed
Phase 2 Combination Therapy With Carfilzomib for the Antibody-Mediated Rejection Diagnosis in Lung Transplantation Completed
Phase 2 High Dose Carfilzomib for Newly Diagnosed Myeloma Completed
Phase 2 Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or Lymphoma Completed
Phase 2 Carfilzomib in Treating Patients With Chronic Graft-Versus-Host Disease Completed
Phase 2 Carfilzomib, Pegylated Liposomal Doxorubicin Hydrochloride, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma Completed
Phase 2 A Study of Extended Carfilzomib Therapy for Patients Previously Enrolled in Carfilzomib Treatment Protocols Completed
Phase 1 A Multicenter, Open-label, Phase 1b Study of Carfilzomib, Cyclophosphamide and Dexamethasone in Newly Diagnosed Multiple Myeloma Subjects Completed
Phase 1 Phase 1b Multicenter Study of Carfilzomib With Lenalidomide and Dexamethasone in Relapsed Multiple Myeloma Completed
Phase 1 Study of the Pharmacokinetics and Safety of Carfilzomib in Patients With Multiple Myeloma and Renal Disease Completed

Showing the 50 most-cited and recently-updated of 54 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.